

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 5, 2018

**SECOND SIGHT MEDICAL PRODUCTS, INC.**  
(Exact Name of Registrant as Specified in Its Charter)

**California**  
(State or Other Jurisdiction of Incorporation)

**333-198073**  
(Commission File Number)

**02-0692322**  
(IRS Employer Identification No.)

**12744 San Fernando Road, Suite 400**  
**Sylmar, California 91342**  
(Address of Principal Executive Offices)

**(818) 833-5000**  
(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## ITEM 7.01. REGULATION FD DISCLOSURE

A copy of a slide presentation that Second Sight Medical Products, Inc. ("Second Sight") intends to use during a presentation at the Annual LD Micro Main Event Conference in Los Angeles on December 5, 2018 (the "Presentation Materials") is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated by reference herein. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Second Sight may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Second Sight specifically disclaims any obligation to do so. Additionally, the Annual LD Micro Main Event Conference presentation will be webcast at 5:00 P.M. Pacific Standard Time at <http://wsw.com/webcast/ldmicro15/eyes/>. The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company's website at [www.secondsight.com](http://www.secondsight.com), under the Investors section. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

## ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

### Exhibit No. Description

99.1 [Second Sight Medical Products, Inc. Investor Presentation dated December 5, 2018.](#)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 5, 2018

**SECOND SIGHT MEDICAL PRODUCTS, INC.**

/s/ John T. Blake  
By: John T. Blake  
Chief Financial Officer



# Second Sight Medical Products, Inc.

11th Annual LD Micro Main Event  
December 5, 2018

**SECONDSIGHT**  
Life In A New Light™  
(NASDAQ: EYES)


# Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form 10-K, filed on March 20, 2018, our most recent 10-Q, filed on November 8, 2018 and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.

# Two Breakthrough Technologies


## Argus® II Retinal Prosthesis

- First and only FDA approved retinal prosthesis
- 20+ years and ~\$200 million invested to develop and commercialize
- Established technology with 293+ implants
- Approved for individuals with advanced retinitis pigmentosa (bare-light and no-light perception in U.S.)



## Orion® Visual Cortical Prosthesis


- Transformational technology with U.S. human trial initiated in Q1 2018
- Broad label potential for most causes of blindness including glaucoma, diabetic retinopathy, optic nerve disease and trauma
- Bypasses the retina and optic nerve to directly stimulate the portion of the brain responsible for vision



SECONDSIGHT

# Argus® II: Effective Treatment for Blindness

**Argus II is a retinal prosthesis that induces visual perception in individuals with advanced retinitis pigmentosa (RP)**



4

Video Link: <https://youtu.be/ezVNM05GeUE>

SECONDSIGHT

---

# Strategy Driven by Growing Confidence in Orion®



## Execute Orion clinical and R&D programs as our top priority

- Six subject U.S. feasibility study at UCLA and Baylor is ongoing
- R&D efforts to iterate cortical prosthesis and external components in preparation for pivotal trial
- Orion designated FDA Breakthrough Device for expedited pathway to commercialization



## Improve the artificial vision user experience

- Multiple research projects to enhance visual acuity and create a richer user experience
- Examples include object and facial recognition, distance filtering, thermal imaging and eye tracking
- Technologies can be integrated in Argus and Orion platforms




## Build and leverage commercial capabilities with capital efficiency

- Focus on markets and Centers of Excellence (COE) with near-term ROI and highest impact
- Restructuring completed in Europe to reduce annual commercial spend by approximately \$3 million
- Build market development and artificial vision rehab competencies required for Argus and Orion

# Orion®: Breakthrough Device with Potential to Treat Virtually All Forms of Blindness

*The addressable market for Orion is potentially over 70,000 individuals in the U.S.;  
a multi-billion dollar market opportunity*



Approximately  
**50x**  
current addressable market in the U.S.

SECONDSIGHT



# Encouraging Early Orion<sup>®</sup> Feasibility Study Results

- Conducting a six subject feasibility study at Ronald Reagan UCLA Medical Center and the Baylor College of Medicine
  - Five subjects implanted and activated in 1H 2018
  - Recruiting sixth patient at Baylor College of Medicine
- Observations from our early testing include the following:
  - Four patients cleared for home use
  - Stimulation parameters are within expected ranges and field of view appears to be larger than Argus
  - Observations from rehab sessions indicate subjects are able to do things with Orion that they could not do without, including:
    - Locating people in front of them
    - Identifying drop-off of curb and locating signs
    - Sorting light from dark laundry



***Performance data from feasibility patients will be used to determine next steps in 2019 including discussions with FDA to finalize clinical and regulatory pathway as part of Breakthrough Devices program***

# Research Technologies to Enhance User Experience

## Eye Tracking

Move the implant field of view in conjunction with the movement of the user's eyes

## Thermal Imaging

Infrared imaging would allow users to visualize warm objects such as people in a room



## Depth-Based Decluttering

Allow users to filter out objects further than a defined distance

## Object & Facial Recognition

Receive additional auditory and/or haptic information integrated with their artificial vision


*Research projects have potential to benefit Argus and Orion users*

# Argus® II Strategy: Capital Efficiency & Building Strategic Value

## Execute Argus II business with capital efficiency



- High bar for new markets or expansion in current markets
- Improve cost structure and utilization of commercial team
- Focus on Centers of Excellence



## Develop Argus II commercial competencies that are strategic for Orion



- Patient outreach, patient qualification and U.S. patient database
- Artificial vision rehabilitation expertise



## Invest in Argus II R&D that benefits Orion



- Argus externals including eyewear, camera and VPU
- Software and proprietary software/algorithms used to create artificial vision

# Orion® Leverages our Commercial Experience & Argus II Technology



## Centers of Excellence (COE) model and artificial vision rehabilitation

- Centers of Excellence model to build regional artificial vision centers for Argus and Orion
- Best practices development and pioneered post-surgical rehabilitation to improve patient satisfaction and outcomes for all artificial vision patients



## Effective patient outreach & screening with U.S. patient database

- Effective patient outreach programs and a multi-step patient qualification process applicable to Argus and Orion
- Large and growing U.S. database that includes potential Argus and Orion patients



## Market access & reimbursement expertise benefits Orion

- Argus is an established therapy in over a dozen markets globally
- Achieved highest CMS outpatient reimbursement rate in U.S. at \$152.5k for 2019
- Conducting clinical studies via Forfait Innovation (France) and Commissioning Through Evaluation (England) programs for national reimbursement




## Orion leverages Argus II technology platform

- Established technology with 10 years+ proven implant durability
- Proprietary algorithms for artificial vision




SECONDSIGHT


# Innovative Pipeline Extends our Leadership Position



# Key Drivers of Shareholder Value through 2019

## Orion

-  Complete Orion feasibility trial and release interim data from first six subjects
-  Agreement on pivotal and post-market trial designs via the FDA's Breakthrough Device Program
-  Initiation of U.S. Orion pivotal trial



# Select Financial Data

| (USD \$ in thousands)                   | Q3 2018   | FY 2017                        | FY 2016                       |
|---|-----------|--------------------------------|-------------------------------|
| <b>Implants</b>                         | <b>20</b> | <b>75</b><br><i>(30 in Q4)</i> | <b>42</b><br><i>(7 in Q4)</i> |
| Revenue                                 | \$2,246   | \$7,964                        | \$3,985                       |
| Gross Profit (Loss)                     | \$462     | \$2,847                        | \$(6,091)                     |
| Net Loss                                | \$(8,522) | \$(28,516)                     | \$(33,179)                    |
| Non-GAAP Adjusted Net Loss <sup>1</sup> | \$(7,535) | \$(27,576)                     | \$(24,812)                    |

1) Non-GAAP adjusted net loss excludes non-cash expenses including stock-based compensation and reserve for excess inventory.

| (USD \$ in thousands)  | September 30, 2018 | December 31, 2017 |
|--|--------------------|-------------------|
| Cash and cash equivalents  | \$4,972            | \$7,839           |
| <i>Cash balance above does not include \$4.0 million private placement of common stock with Gregg Williams, Chairman of the Board of Directors in October 2018</i> |                    |                   |
| Debt   | \$0                | \$0               |

# Second Sight Investment Highlights

- **Argus II business focused on capital efficiency and strategic benefit**
  - ROI and cost structure improvements important when evaluating markets or expansion
  - Commercial competencies and R&D efforts such as Argus 2s next-gen externals that benefit Orion are prioritized
- **Orion is a large market opportunity that's more than 50x the current RP market**
  - Potential to treat nearly all forms of blindness including diabetic retinopathy, glaucoma, optic nerve disease and eye injury
  - Six subject feasibility study at UCLA and Baylor underway with good early results and interim data in next six months
  - FDA Breakthrough Device designation provides expedited regulatory and clinical pathway
- **Orion leverages Argus II**
  - Orion leverages Argus technology including implantable array, externals and proprietary software / algorithms for creating artificial vision
  - Orion also leverages reimbursement success, patient outreach and screening expertise as well as artificial vision rehabilitation competencies
- **Future technologies under development beneficial to Argus II and Orion**
  - Eye-tracking, thermal imaging and depth-based decluttering provide improved or more useful vision
  - Object recognition and facial recognition create enhanced user experience





# Contacts

**Second Sight Medical Products, Inc.**  
12744 San Fernando Road  
Suite 400  
Sylmar, CA 91342  
Main: 818-833-5000  
[www.secondsight.com](http://www.secondsight.com)

Will McGuire  
President & CEO  
Direct: 818-833-5040  
[wmcguire@secondsight.com](mailto:wmcguire@secondsight.com)

**Retail Investor Relations**  
Greg Falesnik  
Managing Director  
MZ North America  
Direct: 949-385-6449  
[Greg.Falesnik@mzgroup.us](mailto:Greg.Falesnik@mzgroup.us)

**Institutional Investor Relations**  
Lisa Wilson  
President  
In-Site Communications, Inc.  
Direct: 212-452-2793  
[lwilson@insitecony.com](mailto:lwilson@insitecony.com)

SECONDSIGHT